Clinical pretrial for the evofosfamide (TH-302) were thought to have failed. Later, observations contradicted there initial results with almost 50%—improvement in the overall survival in Japanese and South Korean patients in the trial.
We have had plenty of good news with the stock but still no rise, I guess we will have to wait for the 1Q results which I think should be in within the next week or 2.
News 
Market Data 
Discover 
